NASDAQ:FGEN

FibroGen Stock Insider Trading

NASDAQ Stock Exchange > Healthcare > Biotechnology

$0.399

-0.0010 (-0.250%)

At Close: Oct 03, 2024

FibroGen Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 79.58. In total, the insiders bought 3 706 106 and sold 335 031 FGEN shares in the last 100 trades.

Insider Power (Last 100 transactions)	79.58
Buy	3 706 106 Shares
Sell	335 031 Shares

Historical Insider Trades

Date	Type	Action	Person	Amount
Sep 07, 2024	Common Stock	Sell	Graham Juan	1 065
Sep 06, 2024	Common Stock	Sell	Graham Juan	16 050
Sep 06, 2024	Common Stock	Sell	Wettig Thane	2 363
Sep 06, 2024	Common Stock	Sell	Chung Christine	17 395
Aug 01, 2024	Common Stock	Sell	Wettig Thane	20 840
Jun 22, 2024	Common Stock	Sell	Wettig Thane	782
Jun 12, 2024	Common Stock	Buy	Adib Deyaa	22 123
Jun 07, 2024	Common Stock	Sell	Graham Juan	1 182
Jun 06, 2024	Common Stock	Sell	Graham Juan	17 797
Jun 06, 2024	Common Stock	Sell	Chung Christine	19 289
Jun 06, 2024	Common Stock	Sell	Wettig Thane	2 255
Jun 05, 2024	Stock Option (Right to Buy)	Buy	Schoeneck James A	70 000
Jun 05, 2024	Stock Option (Right to Buy)	Buy	Lema Gerald	70 000
Jun 05, 2024	Stock Option (Right to Buy)	Buy	Ho Maykin	70 000
Jun 05, 2024	Stock Option (Right to Buy)	Buy	Cravatt Benjamin	70 000
Jun 05, 2024	Stock Option (Right to Buy)	Buy	Brennan Aoife	70 000
Jun 05, 2024	Stock Option (Right to Buy)	Buy	Edwards Jeffrey L	70 000
Jun 05, 2024	Stock Option (Right to Buy)	Buy	Blaug Suzanne	70 000
May 01, 2024	Common Stock	Sell	Wettig Thane	20 840
Apr 22, 2024	Common Stock	Buy	Adib Deyaa	0
Apr 22, 2024	Stock Option (Right to Buy)	Buy	Adib Deyaa	300 000
Mar 22, 2024	Common Stock	Sell	Wettig Thane	782
Mar 07, 2024	Common Stock	Buy	Wettig Thane	50 000
Mar 07, 2024	Common Stock	Sell	Graham Juan	1 181
Mar 06, 2024	Common Stock	Buy	Graham Juan	781

ABOUT FIBROGEN

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China ...

Read Full Profile Here